Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Unilever's soap opera: M&A, job cuts and grumpy investors

Published 01/25/2022, 06:31 AM
Updated 01/25/2022, 06:36 AM
© Reuters. FILE PHOTO: Unilever logo is displayed in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

© Reuters. FILE PHOTO: Unilever logo is displayed in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

(Reuters) - Unilever (NYSE:UL) unveiled plans on Tuesday to cut about 1,500 management jobs in an overhaul aimed at easing shareholders' concerns after a failed acquisition and news an activist investor had built a stake in the consumer goods giant.

The maker of Dove soap and Magnum ice cream has had a bumpy few years, with shares falling about a quarter from highs seen in late 2019, and CEO Alan Jope's plans facing scrutiny.

Here are key developments around Unilever in the past two months.

NOV. 18, 2021:

Unilever agreed to sell its global tea business to CVC Capital Partners for 4.5 billion euros ($5.1 billion), concluding a process of reviewing and spinning off the division that took more than two years.

JAN. 15, 2022:

Unilever confirmed it had approached GlaxoSmithKline (NYSE:GSK) about buying its consumer goods business following media reports.

Later in the day, GSK said it had rejected Unilever's 50-billion-pound ($68 billion) offer, saying it "fundamentally undervalued" the consumer healthcare business.

GSK said it had received the third approach from Unilever on Dec. 20 and that it comprised 41.7 billion pounds in cash and 8.3 billion in Unilever shares.

JAN. 17

Unilever signalled it would pursue a deal for GSK's consumer business, calling it a "strong strategic fit," but shares slid more than 8%. The company also said it would announce an initiative later in the month to strengthen its business.

JAN. 19

Late in the day, Unilever said it would not raise its offer for GSK's consumer healthcare business from 50 billion pounds. Sources had told Reuters GSK would not engage with Unilever unless the offer was sweetened.

JAN. 20

Unilever shares slipped on its short-lived pursuit of GSK's consumer health assets. Influential British fund manager Terry Smith criticised the failed bid as a "near death experience" and urged Unilever to focus on strengthening performance.

JAN. 23

A source told Reuters that activist investor Nelson Peltz's hedge fund, Trian Partners, had built a stake of an unspecified size in Unilever, ratcheting up pressure on the company, months after Peltz stepped down from rival P&G's board.

© Reuters. FILE PHOTO: Unilever logo is displayed in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration

JAN. 24

Unilever shares rose 6% on reports of Peltz's stake.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.